Ultragenyx preliminary 2024 revenue $555-560M above guidance; 2025 guide $640-670M

Ultragenyx Pharmaceutical Inc.

2024-FY EPS reported -$6.29 revenue$560,230,000

Preliminary 2024 total revenue $555-560M, exceeding top end of guidance, ~29% YoY growth.
Crysvita revenue $405-410M (+24% YoY); Dojolvi revenue $87-89M (+25% YoY).
2025 total revenue guidance $640-670M; cash and investments ~$745M as of Dec 31, 2024.
UX143 Phase 3 OI study second interim analysis mid-2025; GTX-102 Phase 3 Angelman enrollment completion H2 2025.
UX111 BLA submitted (PDUFA H2 2025); DTX401 BLA filing mid-2025; DTX301 Phase 3 enrollment early 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.